Furthermore, although dispersion of the data was high, the Sirius Red and F4/80 immunostaining (Fig. 3a) and the expression levels of genes involved in fibrosis and inflammation (Supplementary Fig. 6a), showed that treatment with Mat1a ASO did not induce the increase of liver fibrosis or inflammation. This evidence concerns the gene MAT1A and Hepatic fibrosis.